NIH Reporter #5R01CA272934-04

NIH/NCI Solicitation for Research on WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer

This opportunity is a research grant solicitation from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), focused on prostate cancer research. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Project Scope: - Research services to investigate the role of Wnt5a/ROR2 in activating the Hippo pathway for tumor suppression in prostate cancer - Work to be conducted at Beth Israel Deaconess Medical Center, Boston, MA - Products/Services Requested: - One unit of research service on Wnt signaling in prostate cancer - Notable Requirements: - Emphasis on Wnt5a/ROR2-mediated Hippo pathway activation - Research must have potential therapeutic implications for prostate cancer - No specific OEMs or commercial products are referenced, as this is a research grant opportunity - NAICS codes: 541712 (Research and Development in Biotechnology), 541714 (Research and Development in Biotechnology, except Nanobiotechnology) - Estimated contract value: $395,509

Description

This is a research grant opportunity from the NIH/NCI focusing on prostate cancer and Wnt signaling pathways. The project aims to investigate the role of Wnt5a/ROR2 in activating the Hippo pathway to suppress tumor growth, with potential therapeutic implications. The research is conducted at Beth Israel Deaconess Medical Center in Boston, MA. The project duration is from June 1, 2023 to May 31, 2028, with a response due date of May 26, 2026.

View original listing